Peddock Capital Advisors LLC Sells 256 Shares of Boston Scientific Co. (NYSE:BSX)

Peddock Capital Advisors LLC decreased its holdings in Boston Scientific Co. (NYSE:BSX) by 5.8% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 4,144 shares of the medical equipment provider’s stock after selling 256 shares during the period. Peddock Capital Advisors LLC’s holdings in Boston Scientific were worth $347,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new stake in Boston Scientific during the 3rd quarter worth $326,000. Brookstone Capital Management grew its position in Boston Scientific by 22.3% during the 3rd quarter. Brookstone Capital Management now owns 85,553 shares of the medical equipment provider’s stock worth $7,169,000 after acquiring an additional 15,608 shares during the last quarter. Country Trust Bank bought a new stake in Boston Scientific during the 3rd quarter worth $383,000. Atomi Financial Group Inc. grew its position in Boston Scientific by 13.7% during the 3rd quarter. Atomi Financial Group Inc. now owns 8,266 shares of the medical equipment provider’s stock worth $693,000 after acquiring an additional 997 shares during the last quarter. Finally, Kesler Norman & Wride LLC bought a new stake in Boston Scientific during the 3rd quarter worth $952,000. Institutional investors own 89.07% of the company’s stock.

Insiders Place Their Bets

In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $81.70, for a total transaction of $570,511.10. Following the completion of the sale, the executive vice president now directly owns 37,468 shares of the company’s stock, valued at approximately $3,061,135.60. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, EVP Wendy Carruthers sold 6,983 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $81.70, for a total value of $570,511.10. Following the transaction, the executive vice president now owns 37,468 shares in the company, valued at approximately $3,061,135.60. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Joseph Michael Fitzgerald sold 132,527 shares of the company’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $85.00, for a total value of $11,264,795.00. Following the completion of the transaction, the executive vice president now owns 160,467 shares in the company, valued at approximately $13,639,695. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 316,253 shares of company stock valued at $26,714,298. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Trading Down 0.1 %

Shares of NYSE:BSX traded down $0.11 during midday trading on Wednesday, reaching $85.73. The company’s stock had a trading volume of 2,083,517 shares, compared to its average volume of 5,954,102. Boston Scientific Co. has a fifty-two week low of $48.35 and a fifty-two week high of $86.09. The firm has a market capitalization of $125.77 billion, a price-to-earnings ratio of 72.13, a PEG ratio of 2.78 and a beta of 0.80. The firm has a 50 day moving average price of $80.48 and a two-hundred day moving average price of $76.16. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.14 and a current ratio of 1.61.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, July 24th. The medical equipment provider reported $0.62 EPS for the quarter, beating analysts’ consensus estimates of $0.58 by $0.04. Boston Scientific had a return on equity of 16.59% and a net margin of 12.00%. The business had revenue of $4.12 billion during the quarter, compared to analyst estimates of $4.02 billion. During the same period in the previous year, the company posted $0.53 EPS. The firm’s revenue was up 14.5% compared to the same quarter last year. As a group, analysts forecast that Boston Scientific Co. will post 2.4 earnings per share for the current year.

Analysts Set New Price Targets

BSX has been the topic of a number of research reports. Deutsche Bank Aktiengesellschaft boosted their price objective on Boston Scientific from $73.00 to $78.00 and gave the stock a “hold” rating in a research report on Thursday, July 25th. Raymond James lifted their target price on Boston Scientific from $91.00 to $94.00 and gave the stock a “strong-buy” rating in a report on Wednesday, September 4th. Needham & Company LLC lifted their target price on Boston Scientific from $82.00 to $86.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. JPMorgan Chase & Co. lifted their target price on Boston Scientific from $82.00 to $85.00 and gave the stock an “overweight” rating in a report on Thursday, July 25th. Finally, Morgan Stanley lifted their target price on Boston Scientific from $79.00 to $92.00 and gave the stock an “overweight” rating in a report on Monday, July 15th. Three analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Boston Scientific has a consensus rating of “Moderate Buy” and a consensus price target of $87.60.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.